跳至主要内容
临床试验/NCT01391273
NCT01391273已完成3 期

A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-Daily Application of Bimatoprost Solution 0.03% Compared to Vehicle in Increasing Overall Eyelash Prominence in Japanese Subjects With Hypotrichosis of the Eyelashes

Allergan0 个研究点目标入组 173 人开始时间: 2011年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Allergan
入组人数
173
主要终点
Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)

研究概览

简要总结

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Have inadequate eyelashes

排除标准

  • •Any disease/infection/abnormality of the eye or area around the eye
  • •Any ocular surgery within 3 months or anticipated need for ocular surgery during the study
  • •Any permanent eyeliner or implants of any kind or anticipated use of false eyelashes
  • •Any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months
  • •Use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products
  • •Use of treatments which may affect hair growth (eg, minoxidil, chemotherapy) within 6 months

研究组 & 干预措施

bimatoprost solution 0.03%

Experimental

One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.

干预措施: bimatoprost solution 0.03% (Drug)

bimatoprost vehicle solution

Placebo Comparator

One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.

干预措施: bimatoprost vehicle solution (Drug)

结局指标

主要结局

Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA)

时间窗: Baseline, Month 4

The investigator evaluated the patient's eyelash prominence using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked at Baseline and Month 4. At least a 1-grade increase in the GEA score from Baseline indicated improvement.

次要结局

  • Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA)(Baseline, Month 4)
  • Change From Baseline in Eyelash Thickness as Measured by DIA(Baseline, Month 4)
  • Change From Baseline in Eyelash Darkness as Measured by DIA(Baseline, Month 4)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验